Patents Examined by Channing S. Mahatan
  • Patent number: 11414695
    Abstract: A method of enriching for a fragment of a genome, as well as corresponding compositions and kits, are provided. In certain embodiments, the method comprises: (a) contacting a sample comprising fragmented DNA with a Cas9-gRNA complex comprising mutant Cas9 protein that has inactivated nuclease activity and a Cas9-associated guide RNA that is complementary to a site in the DNA, to produce a Cas9-fragment complex that comprises a fragment of the fragmented DNA; and (b) isolating the complex. In addition, other methods and compositions for Cas9/CRISPR-mediated nucleic acid manipulation are also provided.
    Type: Grant
    Filed: May 29, 2014
    Date of Patent: August 16, 2022
    Assignee: Agilent Technologies, Inc.
    Inventors: Brian Jon Peter, Robert A. Ach
  • Patent number: 11401521
    Abstract: The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel transposons and transposases that further improve expression. Further disclosed are vectors that can be used in a gene transfer system for stably introducing nucleic acids into the DNA of a cell. The gene transfer systems can be used in methods, for example, gene expression, bioprocessing, gene therapy, insertional mutagenesis, or gene discovery.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: August 2, 2022
    Assignee: DNA TWOPOINTO INC.
    Inventors: Jeremy Minshull, Sridhar Govindarajan, Maggie Lee
  • Patent number: 11371046
    Abstract: The invention provides a non-naturally occurring microbial biocatalyst including a microbial organism having a 4-hydroxybutanoic acid (4-HB) biosynthetic pathway having at least one exogenous nucleic acid encoding 4-hydroxybutanoate dehydrogenase, succinyl-CoA synthetase, CoA-dependent succinic semialdehyde dehydrogenase, or ?-ketoglutarate decarboxylase, wherein the exogenous nucleic acid is expressed in sufficient amounts to produce monomeric 4-hydroxybutanoic acid (4-HB).
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: June 28, 2022
    Assignee: Genomatica, Inc.
    Inventors: Mark J. Burk, Stephen J. Van Dien, Anthony P. Burgard, Wei Niu
  • Patent number: 11367508
    Abstract: Disclosed herein are systems, methods, and compositions useful for determining cellular pathway disruption comprising the use of RNA expression level information. This determined level of disruption can assist in the identification of genetic variants that alter pathway activity, to correlate these variants with disease state and disease progression, and to identify those therapeutics most likely to be effective and which should be avoided.
    Type: Grant
    Filed: August 14, 2020
    Date of Patent: June 21, 2022
    Assignee: Tempus Labs, Inc.
    Inventors: Nike T. Beaubier, Joshua S K Bell, Catherine Igartua, Hailey B. Lefkofsky, Lee F. Langer, Joshua Drews
  • Patent number: 11355220
    Abstract: A method for coordinating data between a plurality of sample processing systems is disclosed. In some implementations, the method comprises providing, using a central control unit, data to a pre-analytical sample processing system identifying a sample undergoing pre-analytical processing, receiving data, at the central control unit, indicating the transfer of the sample to an analytical system, providing, from the central control unit (CCU), data associated with the sample to the analytical system, and receiving a result associated with the sample from the analytical system.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: June 7, 2022
    Assignee: BECTON, DICKINSON AND COMPANY
    Inventors: John Scott, Lauren Hannon, Jason Troxell, Emmet Brown
  • Patent number: 11339408
    Abstract: The present disclosure provides a composition comprising a site-specific nuclease domain capable of cleaving a target DNA sequence; and a sequence-specific DNA binding domain capable of specifically binding to a recognition DNA sequence, wherein the site-specific nuclease domain operably links to the sequence-specific DNA binding domain.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: May 24, 2022
    Assignee: APPLIED STEMCELL, INC.
    Inventors: Ruby Yanru Tsai, Ling-jie Kong, Jingyuan Cao
  • Patent number: 11332728
    Abstract: The present disclosure relates to recombinant yeast strains capable of maintaining their robustness at high temperature as well as recombinant proteins expressed therefrom. The present disclosure also provides methods for using the recombinant yeast strain for making a fermentation product. The present disclosure further process a process for making recombinant yeast strains capable of maintaining their robustness at high temperature.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: May 17, 2022
    Assignee: Lallemand Hungary Liquidity Management LLC
    Inventors: Charles F. Rice, Ryan Skinner, Trisha Barrett, Aaron Argyros
  • Patent number: 11328790
    Abstract: Provided herein are biomarkers of endogenous biological time (e.g. circadian time). In particular compositions and methods are provided for assessing the biological time of a subject, and diagnosis of diseases/conditions and/or providing treatments based thereon.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: May 10, 2022
    Assignee: Northwestern University
    Inventors: Rosemary Braun, Ravi Aliada, Phyllis Zee
  • Patent number: 11319530
    Abstract: Provided herein are host cells or host cellular expression systems that express a membrane protein. Also, methods are provided that use such host cells or host cellular expression systems to produce higher amounts of the membrane proteins. Further, the cells or cellular systems can be used as tools for the functional characterization of membrane proteins, as well as for screening and drug discovery efforts targeting membrane proteins.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: May 3, 2022
    Assignee: President and Fellows of Harvard College
    Inventors: Jonathan Beckwith, Dana Boyd, Jessica Blazyk, Feras Hatahet
  • Patent number: 11306306
    Abstract: The present disclosure provides methods to identify peptides and small molecule moieties that are able to functionally bridge an interaction between a target protein and an E3 ubiquitin ligase to mediate the degradation of the target protein. Some moieties can degrade specific target variants, but not others. The moieties create a neosubstrate for an E3 ligase of interest. The methods described enable generation of compounds able to selectively degrade specific targets within cells with implications for drug development for pathological conditions. The disclosure also describes the generation of modified peptides using post-translational modification enzymes, such as N-methyltransferases, prolyloligopeptidases, lactamases, hydroxylases, and dehydratases, along with methods of using the same.
    Type: Grant
    Filed: May 11, 2021
    Date of Patent: April 19, 2022
    Assignee: SYNTHEX, INC.
    Inventors: Charly Chahwan, Maria Soloveychik
  • Patent number: 11299729
    Abstract: Strategies, reagents, methods, and systems for modulating the mutation rate in cells are provided herein. The strategies, reagents, methods, and systems are broadly applicable for the modulation of mutation rates in cells where high mutation rates and/or control over a broad range of mutation rates is desired, for example, in the context of diversifying a nucleic acid sequence or a plurality of such sequences within a population of cells, for the generation of diversified nucleic acid libraries, and for directed evolution of nucleic acids and encoded products.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: April 12, 2022
    Assignee: President and Fellows of Harvard College
    Inventors: Ahmed Hussein Badran, David R. Liu
  • Patent number: 11299748
    Abstract: A kit for constructing a transposon is provided. The kit comprises five plasmids, each of which consists essentially of a gene cassette linked or not linked to a terminal repeat. The kit is useful in selecting the type of piggyBac that exhibits the least enhancer activity in the host cells.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: April 12, 2022
    Inventor: Sareina Chiung-Yuan Wu
  • Patent number: 11286480
    Abstract: The invention relates to antimicrobial compositions comprising cell-penetrating peptides linked to CRISPR RNAs and methods for their use.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: March 29, 2022
    Assignee: NORTH CAROLINA STATE UNIVERSITY
    Inventors: Chase Beisel, Ahmed M. Gomaa
  • Patent number: 11286492
    Abstract: The invention relates to an artificial nucleic acid molecule comprising an open reading frame and a 3?-UTR comprising at least one poly(A) sequence or a polyadenylation signal. The invention further relates to a vector comprising the artificial nucleic acid molecule comprising an open reading frame and a 3?-UTR comprising at least one poly(A) sequence or a polyadenylation signal, to a cell comprising the artificial nucleic acid molecule or the vector, to a pharmaceutical composition comprising the artificial nucleic acid molecule or the vector and to a kit comprising the artificial nucleic acid molecule, the vector and/or the pharmaceutical composition. The invention also relates to a method for increasing protein production from an artificial nucleic acid molecule and to the use of a 3?-UTR for a method for increasing protein production from an artificial nucleic acid molecule.
    Type: Grant
    Filed: August 20, 2021
    Date of Patent: March 29, 2022
    Assignee: CureVac AG
    Inventors: Andreas Thess, Thomas Schlake, Stefanie Grund
  • Patent number: 11274309
    Abstract: The present invention relates to a two-part device, wherein a first part is a multicomponent TCR ORF reconstitution and engineering system (TORES), and a second part is a multicomponent engineered TCR-presenting cell system (eTPCS).
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: March 15, 2022
    Assignee: GENOVIE AB
    Inventors: Reagan Micheal Jarvis, Ryan Edward Hill, Luke Benjamin Pase
  • Patent number: 11268105
    Abstract: The present invention encompasses compositions and methods to rejuvenate cells by, expanding the replicative life span of the cells for, e.g., use in regenerative therapies. Specifically, the methods and compositions of the present invention increase the proliferation capacity and differentiation capacity and plasticity of cells.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: March 8, 2022
    Assignee: CarryGenes Bioengineering
    Inventors: Edward Perkins, Amy Greene, Dominique Broccoli
  • Patent number: 11261451
    Abstract: This invention relates to the use of CRISPR nucleic acids to screen for essential and non-essential genes and expendable genomic islands in bacteria, archaea, algae and/or yeast, to kill bacteria, archaea, algae and/or yeast, to identify the phenotype of a gene or genes, and/or to screen for reduced genome size and/or a gene deletion in bacteria, archaea, algae and/or yeast.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: March 1, 2022
    Assignee: NORTH CAROLINA STATE UNIVERSITY
    Inventors: Rodolphe Barrangou, Kurt M. Selle
  • Patent number: 11254713
    Abstract: In certain embodiments, a recombinant attenuated derivative of a pathogenic Salmonella enterica serovar typhi cell is provided, (a) wherein one or more genes encoding subunits of a stg operon (Salmonella typhi ?stg) are inactivated or deleted resulting in a decrease of Stg adhesin/fimbriae production as compared to genes encoding a wild-type Stg operon (stgABCC?D), and/or (b) the cell comprises a nucleic acid encoding at least one of a gene encoding a subunit of a long polar fimbriae (Lpf) of S. enterica serovar Typhimurium protein. In certain embodiments, vaccines and compositions, and methods of use of the recombinant attenuated derivative of a pathogenic Salmonella enterica serovar typhi cell are provided.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: February 22, 2022
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Kenneth Roland, Amanda M. Tafoya
  • Patent number: 11257569
    Abstract: The present disclosure relates to methods and systems for assessing the risk of a human subject developing a severe response to a Coronavirus infection, such as a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus infection.
    Type: Grant
    Filed: July 6, 2021
    Date of Patent: February 22, 2022
    Assignee: GENETIC TECHNOLOGIES LIMITED
    Inventors: Gillian Sue Dite, Nicholas Mark Murphy, Richard Allman
  • Patent number: 11248258
    Abstract: A method for identifying and characterizing biological parts based on omics datasets and a dual-fluorescent reporter gene system, and a biological part library constructed thereon are provided, relating to a technical filed of biology. The method includes steps of: identifying the biological parts using the omics datasets; constructing a single-fluorescent reporter gene system using a shuttle vector pEZ15Asp as a skeleton for screening and determining fluorescent reporter genes; obtaining a dual-fluorescent reporter gene system skeleton; constructing recombinant plasmids, and finally transforming into competent cells for quantitative analysis of fluorescence intensities. The present invention is convenient and quick, and can screen and identify different biological parts such as RBS, UTRs, promoters, and terminators of different intensities in batch quantitatively in a relatively short time. Moreover, the present invention can quickly expand the biological part library of Z.
    Type: Grant
    Filed: May 9, 2019
    Date of Patent: February 15, 2022
    Assignee: Hubei University
    Inventors: Shihui Yang, Yongfu Yang, Wei Shen, Runxia Li, Ju Huang, Yu Wang, Li Yi, Lixin Ma